

End-to-End n -ary Relation Extraction for Combination Drug Therapies

Yuhang Jiang

Department of Computer Science
University of Kentucky
Lexington, KY USA
yuhang.jiang@uky.edu

Ramakanth Kavuluru

Division of Biomedical Informatics
Dept. of Internal Medicine, Univ. of Kentucky
Lexington, KY USA
ramakanth.kavuluru@uky.edu

Abstract—Combination drug therapies are treatment regimens that involve two or more drugs, administered more commonly for patients with cancer, HIV, malaria, or tuberculosis. Currently there are over 350K articles in PubMed that use the **combination drug therapy** MeSH heading with at least 10K articles published per year over the past two decades. Extracting combination therapies from scientific literature inherently constitutes an n -ary relation extraction problem. Unlike in the general n -ary setting where n is fixed (e.g., drug-gene-mutation relations where $n = 3$), extracting combination therapies is a special setting where $n \geq 2$ is dynamic, depending on each instance. Recently, Tiktinsky et al. (NAACL 2022) introduced a first of its kind dataset, **CombDrugExt**, for extracting such therapies from literature. Here, we use a sequence-to-sequence style end-to-end extraction method to achieve an F1-Score of 66.7% on the **CombDrugExt** test set for positive (or effective) combinations. This is an absolute $\approx 5\%$ F1-score improvement even over the prior best relation classification score with spotted drug entities (hence, not end-to-end). Thus our effort introduces a state-of-the-art first model for end-to-end extraction that is already superior to the best prior non end-to-end model for this task. Our model seamlessly extracts all drug entities and relations in a single pass and is highly suitable for dynamic n -ary extraction scenarios.

Index Terms— n -ary relation extraction, end-to-end relation extraction, named entity recognition, combination drug therapies

I. INTRODUCTION

Combination drug therapies (CDTs) have been on the rise for serious conditions such as cancers and HIV. Nearly half of the papers on PubMed that are tagged with the combination drug therapy MeSH heading are related to cancer treatment. There are at least 10K articles published every year discussing advances in combination drug therapies. As such, there is a need for automatically extracting and creating structured knowledge bases of such therapies. A CDT involves at least two drugs that are used as part of a treatment regimen for a specific disease.¹

Research reported in this paper was supported by the National Library of Medicine of the National Institutes of Health (NIH) under Award Number R01LM013240. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

¹We distinguish this from drug combination (a different MeSH term) typically employed to denote pills or formulations that have two or more ingredients in the same product (e.g., Vicks NyQuil has both acetaminophen and dextromethorphan.) We, however, use the term “combination” in this paper to mean a drug set that is part of a combination therapy regimen.

As CDTs become more prominent due to advances in precision medicine strategies [1], it is important to extract new combinations as reported in scientific literature. However, until recently, we are not aware of any public datasets to extract CDTs from textual data, with the eventual goal of curating large sets of such therapies from scientific literature. The first such dataset and associated extraction baselines were presented by Tiktinsky et al. [2] in 2022. They manually annotated 1600 abstracts with different drug combinations and provided train-validation-test splits for bench marking by other researchers. For the rest of this manuscript we call this dataset **CombDrugExt**. We describe the dataset characteristics and the specifics of the end-to-end n -ary extraction task in Section II.

To begin with, it is straightforward to see that CDT extraction from text is inherently an n -ary relation extraction task, where $n \geq 2$ is dynamic and changes based on each input instance. This is unlike other n -ary relation extraction tasks where n is typically fixed (e.g., drug-gene-mutation relation extraction task where $n = 3$). A simple example of an effective two-drug combination therapy can be seen from the **bold** tokens in the sentence — “**Abiraterone acetate** in combination with **prednisone** was the first approved hormone therapy demonstrating survival benefit in metastatic castration-resistant prostate cancer.” Likewise, a simple negative example of a lack of combination for the two drugs mentioned can be noticed from the **red** tokens in this sentence — “**Atorvastatin** and **simvastatin** (members of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor family) are widely prescribed as cholesterol-lowering agents.” At a high level, the extraction challenge is to spot the drugs and then distinguish drug sets that are discussed as a combination therapy from drug sets that are discussed in other ways (e.g., part of a list or a comparative statement). As the number of drugs in an instance increases, the difficulty also increases in terms of identifying groups of drugs that form a combination compared with other groups that are simply discussed in ways that do not convey a combination.

Since n is not known upfront for the task (it ranges from 2 to 15 in the **CombDrugExt** dataset), we need an extraction approach that dynamically adjusts the grouping without resorting to brute force enumeration, which could quickly lead to an expensive combinatorial explosion of the candidate combination drug set space. This rules out the typical pipeline approach

of recognizing all drugs through named entity recognition (NER) first and then checking if subsets from the list identified represent a CDT. Toward more efficient single-pass CDT extraction, we adapt the sequence-to-sequence style relation extraction approach recently introduced by Giorgi et al. [3], called Seq2Rel.

Sequence-to-sequence models have been originally popularized for machine translation. This is typically carried out in an encoder-decoder architecture where the encoder processes the source sentence with the encoder output used by the decoder to output tokens, in order, of the target sentence. This encoder-decoder setup has been shown to be powerful and flexible enough to represent relation extraction tasks. This was found to be specifically more advantageous in end-to-end settings where negative examples are not explicitly annotated in training data and in n -ary extraction scenarios. The general idea is to have the input sentence processed by the encoder, whose output is then used by the decoder to generate relations as a target sequence. This is done through (1) a so called *linearization schema* that helps represent and interpret the output sequence as relations (more in Section III) and (2) a copy-mechanism where the decoder is constrained to output only tokens that are observed in the sequence input to the encoder (unlike from the full vocabulary of the target language in machine translation). This enables the decoder to output spans of the input text that correspond to entities and special tokens that correspond to relation labels connecting entities.

With this introductory setup, our main contributions in CDT extraction can be summarized as follows

- We adapt the Seq2Rel [3] approach through a linearization schema that fits the end-to-end CDT extraction task for the **CombDrugExt** dataset [2]. We show that a model built with this architecture achieves an end-to-end F1-score that is $\approx 5\%$ better than the **non** end-to-end prior best score for effective drug combination extraction.
- We also develop a modified linearization schema for Seq2Rel that not only outputs relations but also all entities in an exhaustive manner (regardless of whether they participate in a relation). Though this was not a proposed task for **CombDrugExt**, we show that this approach not only helps with drug NER, but also leads to better overall end-to-end relation extraction performance when considering both effective and non-effective combinations.
- We examine patterns in false positives and false negatives through error analysis. We also study how context length affects performance in this approach through simple ablation experiments.

The code to reproduce our results is available here: <https://github.com/bionlproc/end-to-end-CombDrugExt>. The original dataset is already publicly available: <https://github.com/allenai/drug-combo-extraction>.

II. THE **CombDrugExt** DATASET

In this section we outline the characteristics of the **CombDrugExt** dataset, the associated n -ary combination ex-

traction task as designed by Tiktinsky et al. [2], and the end-to-end variation we consider in this paper.

The full dataset consists of 1600 manually annotated abstracts, each of which mentions between 2 and 15 drugs. 840 of these abstracts describe one or more drug combinations that have a positive effect, with the number of drugs in each such combination varying from 2 to 11. The remaining 760 abstracts either contain mentions of drugs that are not used in combination or discuss combinations of drugs that do not have a combined positive effect. The abstracts (with associated annotations) are subdivided into training, validation, and test splits, which we use for our experiments and evaluation.

A. CDT Relation classes

The relations are categorized into three classes: (a). “Positive combination” (POS), where the text suggests that the drugs are used together in a treatment and are described or implied to have a positive effect; (b). “Non-positive combination” (COMB), where the input sentence indicates that the drugs are used together in a treatment, but there is no evidence in the text to suggest that it is effective; (c). “Not a combination” (NOCOMB), referring to an instance where there is no indication in the text to suggest that the drugs are used together at all. An example for each class is shown in Table I (along with the linearized output representations for training/inference, which we discuss a little later in the manuscript). At this juncture it is important to state two important aspects of the task:

- 1) The annotation (and extraction) task setup by Tiktinsky et al. [2] does not involve identifying the target condition or disease for which the combination is being considered. This target is only relevant for the POS and COMB relations as there isn’t a notion of a target for a set of drugs that do not even participate in a combination (i.e., for the NOCOMB class). Even though this is suboptimal, we stick with this task definition introduced by Tiktinsky et al. [2] in the rest of this paper. We intend to extend **CombDrugExt** and the associated task to also identify the target disease for POS and COMB relations in a future effort. For example, the first sentence in Table I would have the target attribute of “hepatocellular carcinoma.”
- 2) Each input instance is provided as an abstract within which a **single sentence** that has all the drugs involved is designated for extraction. As such, this is a sentence level end-to-end extraction task, with the provision of a broader abstract context which contains the sentence². Models ought to process the sentence and may optionally consider the context surrounding it in the full abstract. Multiple combinations are allowed as output for each sentence. We note that Tiktinsky et al. [2] assume that the entities are already spotted and hence solve the relation classification problem; we propose an end-to-end solution that operates on input text without known drug spans.

²We recognize that this is not the most generic formulation; ideally, all entities should not be required to be present in the same sentence. However, considering the setup in the **CombDrugExt** dataset, we make this assumption.

Table I: Examples of different drug combination relations indicating sentences and corresponding linearized model outputs.

Relation Classes	Example	Comment
Positive Combination	<p>INPUT: Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.</p> <p>OUTPUT: sorafenib @DRUG@ curcumin @DRUG@ @POS@</p>	sorafenib and curcumin are an effective combination.
Non-pos. Combination	<p>INPUT: Patients received docetaxel 35 mg/m(2) and irinotecan 60 mg/m(2), intravenously, on Days 1 and 8, every 21 days, until disease progression.</p> <p>OUTPUT: docetaxel @DRUG@ irinotecan @DRUG@ @COMB@</p>	A combination (docetaxel and irinotecan) is employed with no evidence of effectiveness.
Not a Combination	<p>INPUT: The results showed that lamotrigine did not produce any change in cognitive function, while carbamazepine produced cognitive dysfunction.</p> <p>OUTPUT: lamotrigine @DRUG@ carbamazepine @DRUG@ @NOCOMB@</p>	lamotrigine and carbamazepine are used separately.

B. Formal end-to-end task definition

Succinctly, given a sentence that contains drug names and an enclosing context (here, abstract), the end-to-end CDT extraction task is to identify all stated sets of drug spans that correspond to either a POS or COMB relation; for sentences where no such relations exist, output the set of all drug mentions with a NOCOMB label.

More formally, the task is to consider an input instance $X = (C, i)$ where $C = [S_1, \dots, S_n]$ is an ordered list of n sentences (here, all the sentences in an abstract) and $1 \leq i \leq n$ is an index of a sentence S_i that is designated as the input sentence. Let $D(S_i) = \{(d_{start}^1, d_{end}^1), \dots, (d_{start}^m, d_{end}^m)\}$ be the set of $m \geq 2$ spans of drug mentions in S_i (which is not part of the input instance in our end-to-end assumption). The extraction model output should be a result set $R(X) = \{(A_j, y_j)\}$ where $A_j \in \mathcal{P}(D(S_i))$ is a drug combination from the power set of $D(S_i)$ and $y_j \in \{POS, COMB\}$. When X does not contain any combinations, the model output is simply the singleton $R(X) = \{(D(S_i), NOCOMB)\}$.

C. Data and task characteristics

There are already few n -ary tasks in general in biomedical relation extraction as the focus tends to be more on binary relations, which is reasonable. As indicated in prior sections, the dynamic nature of n in this task is unique and it becomes trickier as drugs that are part of a combination and other drugs that are mentioned in a different sense may all occur in the same input sentence. The model ought to separate these two sets and may also need to identify multiple POS/COMB relations within the same sentence — 16% of sentences containing drug combinations in **CombDrugExt** have more than one combination. Around 70% of POS combinations are binary, 19% are 3-ary, and over 5% are 4-ary³. Although the task is in one sense sentence level, the enclosing context of the full abstract is essential in several cases. The drug combination and the evidence whether it is effective may be far apart in the abstract. In fact, in an extreme case, sentences containing the effectiveness evidence and the participating drug names were separated by 41 sentences. Other linguistic phenomena

³Although these were counted to throw light on data characteristics, the proportions were not used in designing or evaluating the model.

including coordination, numerical reasoning, and (biomedical) world knowledge may also need to be considered in arriving at combinations.

III. END-TO-END MODEL FOR CDT EXTRACTION

In this effort, we use the sequence-to-sequence neural architecture Seq2Rel by Giorgi et al. [3], which was designed for flexible end-to-end relation extraction. Compared with pipeline architectures that are particularly expensive for the dynamic n -ary nature of CDT extraction, Seq2Rel can be adapted easily to extract relations (and involved entities) in a single pass. Recall that our input sequence is a sentence with an enclosing full abstract context and the output is a list of 2-tuples each of which is a set of set of drugs and the corresponding label (POS, COMB, or NOCOMB). Before we describe the architecture, we first present the representation of these output 2-tuples.

A. Linearization schema for CDT

A sentence is easy and natural to represent as a sequence. However, representing 2-tuples that correspond to the output for the end-to-end task (as described in Section II-B) needs a clear specification, which we call the linearization schema. It involves special tokens that represent different relation labels in **CombDrugExt** (as shown in Table II) and the special token @DRUG@ to represent a drug entity.

Table II: Special tokens for relations in **CombDrugExt**

Relation labels	Special token
Positive combination	@POS@
Non-positive combination	@COMB@
Not a combination	@NOCOMB@

The representation is straightforward in that it lists all the drug spans forming a combination, in the order that was originally provided by Tiktinsky et al. [2], each followed by the @DRUG@ token with a suitable combination label token (from Table II) as the final token. For a simple example shown in the POS relation in Table I (Row 1), the linearization is shown right below it where the two drugs spans are followed by the @POS@ token. If more than two drugs are part of the combination, all of them are generated before the




Figure 1: The Seq2Rel architecture for CDT extraction with an input sentence and a serialized output of drug combinations

label is output. Outputs with more than one combination are also represented the same way with the combination order determined by the ordering provided by dataset creators [2].

For instance, consider the sentence: “In non-metastatic castration-resistant prostate cancer, two second-generation anti-androgens, **apalutamide** and **enzalutamide**, when used in combination with **ADT**, have demonstrated a significant benefit in metastasis-free survival.” Here the expected output is: **apalutamide @DRUG@ ADT @DRUG@ @POS@ enzalutamide @DRUG@ ADT @DRUG@ @POS@**. Here, **ADT** is used in combination with each of the other two drugs as asserted in the sentence.

B. Model architecture

The Seq2Rel architecture is shown in Figure 1 populated with an example for CDT extraction. A BERT based encoder [4] takes the input sentence (along with accompanying context from the full abstract) and maps each token to a contextual embedding. A single layer LSTM [5] serves as the decoder for generating the serialized output sequence as discussed in Section III-A. The probability $P(Y|X)$ for the serialized representation Y of $R(X)$ (from Section II-B) for input X is computed using the chain rule involving probability estimates for prefixes of Y given X as is common in encoder-decoder architectures for sequence-to-sequence modeling. The loss function is the average cross-entropy per target word. We refer the reader to Chapter 9.7 of Jurafsky and Martin [6] for further details.

Given this setup is prone to generating arbitrary tokens that do not appear in the input sequence (as the output sequence is typically taken from the entire vocabulary), generation is

restricted to special tokens and only tokens from the input sentence through a copy mechanism [7] as implemented by Giorgi et al. [3]. This allows the decoder to obtain a probability distribution over input and special tokens at each time step, thus ensuring that only expected units are generated in the serialized output.

C. Implementation, training, and post-processing

We used PubMedBERT [8] as the encoder given it is pretrained from scratch with PubMed abstracts and articles and was also used by the baselines for this task [3]. The single layer LSTM with random initialized weights was used. We trained the model for 130 epochs, with a learning rate of $2e-5$ for encoder and a learning rate of $1.21e-4$ for decoder. We trained the model on Google Colab (<https://colab.research.google.com>), which took nearly 2.5 hours.

Due to how WordPiece tokenization works in BERT models, we noticed our model outputs extra spaces around the hyphen (“-”) character in drugs containing it. As an example, consider the sentence: “Nal-IRI with **5-fluorouracil** (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer-the NIFE trial.” Note the extra spaces around hyphen in the serialized output: “**5 - fluorouracil @DRUG@** leucovorin @DRUG@ @COMB@ gemcitabine @DRUG@ cisplatin @DRUG@ @COMB@.” So we simply post-processed such outputs to remove these extra spaces (around hyphens) to match strings in the input sentence.

IV. MAIN EXPERIMENTS AND RESULTS

We evaluate our model based on the F1-score (for comparison with prior efforts) while examining both precision and

recall. We use the “exact match” criterion where a relation is correct if (a). all drugs in the combination are identified and match the gold spans and (b). the relation label is correct. With this notion of correctness, F1-score is the harmonic mean of

$$\text{Recall} = \#correct_relations / \#all_gold_relations \quad \text{and}$$

$$\text{Precision} = \#correct_relations / \#predicted_relations.$$

There are two types of evaluations reported in the original effort by Tiktinsky et al. [2] and we do the same here. The first one is the F1-score for POS class and the second one is a relaxed setup where POS and COMB classes are combined into the same class ANY-COMB and report its F1-score. The natural way to model the original 3-class setup is to use all three tags (from Table II), which inherently gives per-class F1-scores. But to compute the ANY-COMB scores, we just collapse the POS and COMB labels to the same ANY-COMB label and compute the ANY-COMB F1-score.

A slightly different way is to use a 2-class set up during the training and testing through a different labeling scheme upfront. For the POS classifier, we simply use two tags: @POS@ and @NON-POS@, where the latter is the tag given to instances in the union of COMB and NOCOMB. For the ANY-COMB classifier, we use a new tag @ANY-COMB@ for instances in the union of POS and COMB classes and the @NOCOMB@ is the tag for the other class. We show the scores obtained through both the 3-class and 2-class modeling in Table III⁴. We note that both approaches achieved similar scores. The the 3-way setup results in a slightly better POS score and the 2-way labeling improves by 1.6% in ANY-COMB F1-score compared with the 3-class approach. Precision and recall are also close to each other but overall recall is slightly less than precision.

Table III: Our main results (precision, recall, F1-score) using 3-way and 2-way classifier modeling for CDT extraction.

Methods	POS Combination			Any Combination		
	F_1	P	R	F_1	P	R
3-way classification	66.7	68.1	65.3	71.1	73.5	68.9
2-way classification	66.4	69.1	64.0	72.7	74.1	71.3

Next, we compare our results with prior state-of-the-art in Table IV, where the last row contains the F1-scores of our 3-way model (from Table III). We see that for both POS and ANY-COMB settings, our Seq2Rel model has better performance. Compared with the penultimate row, which shows the prior SoTA score on this dataset, we have an almost 5% improvement in POS score even though our model is end-to-end while all other rows in the table assume drugs names are spotted. All other models are trained with the PURE method [10], a span-based approach where entity markers are used to glean signal for relation classification. The gains for ANY-COMB are not

⁴Note that the first row of this table is computed using a single 3-way classifier while the second row is based on two binary classifiers.

as substantial (a 1.7% improvement over prior SOTA) using this approach. However, the 2-way model (from Table III) produced a 3.3% improvement in ANY-COMB F1-score.

If we look at per-class F1-scores for non-POS classes, the 3-way model has an F1-score of 70.5% for NOCOMB, but it only has an F_1 score of 26.3% on COMB class; this is to be expected as COMB (non-positive combinations) is the least frequent class in the dataset (nearly 23% of training data) and it is harder to distinguish it from the more frequent POS class. Furthermore, Tiktinsky et al. [2] also convey that for over 2/3 of the instances manual annotation necessitated consideration of additional context outside the sentence containing the drug names. But all results shown in Tables III and IV are trained on just the sentence containing the drug names. However, our results on including additional context from the enclosing full abstract context were underwhelming (more later).

V. ABLATION AND ERROR ANALYSES

To get at the relative importance of different ingredients of our models, we ran a small ablation experiment for the 2-way ANY-COMB model shown in Table III (2nd row). In Table V, we observe that removing the 2-way approach and moving to a 3-way approach results in a 1.6% dip in the score. If we remove the post-processing step involving hyphenated entities (as discussed in Section III-C), the performance decreases by around 4%. This is not surprising because 10% of entities contain at least one hyphen in the training data. The final row in Table V shows the scores if we used a simple semicolon (;) symbol instead of the special @DRUG@ token to denote and separate drug entities in the linearization schema (Section III-A). Since there is only one entity type involved, we thought entity-specific tags may not be necessary. However, we see that using “;” instead of @DRUG@ lowers F1-score by over 3%. This is potentially due to the role semicolon plays in general English and overloading its functionality to also represent drug entities may have had unintended consequences in the final model.

We now discuss four different types of errors we often noticed in the model output.

- 1) **Handling many-to-one attachments:** These are sentences where a drug is described to be used in combination with another drug from a list of candidates, leading to multiple combinations each with two drugs. In these cases, the language may be misinterpreted by our model to create larger combinations with more than two drugs. For example, consider the sentence: “After successful phase II studies, recent phase III trials established combinations of **chlorambucil** with anti-CD20 antibodies such as **rituximab**, **ofatumumab** and **obinutuzumab** as a valuable treatment option for these patients.” Here the gold prediction has three combinations each with two drugs: **chlorambucil @DRUG@ rituximab @DRUG@ @POS@ chlorambucil @DRUG@ ofatumumab @DRUG@ @POS@ chlorambucil @DRUG@ obinutuzumab @DRUG@ @POS@ @POS@**. However, the model incorrectly predicted a

Table IV: Our results (last row) compared with different baseline foundation models (DAPT means with continued domain-adaptive pretraining [9]) trained with the PURE method [10]. The baseline results (first 5 rows) are from Tiktinsky et al. [2].

Model	Positive Combination F_1	Any Combination F_1
PURE (w/SciBERT)	44.6	50.2
PURE (w/BlueBERT)	41.2	47.3
PURE (w/BioBERT)	45.4	46.7
PURE (w/PubMedBERT)	50.7	55.9
PURE (w/PubMedBERT+DAPT)	61.8	69.4
Seq2Rel (w/PubMedBERT) (end-to-end)	66.7	71.1

Table V: ANY-COMB ablated F_1 scores on the test set.

Model	ANY-COMB F_1
Full 2-way model	72.7
w/o. 2-way classification	71.1
w/o. post-processing	68.8
w/o. @DRUG@ entity type token	69.5

combination with all four drugs mentioned: **chlorambucil** @DRUG@ **rituximab** @DRUG@ **ofatumumab** @DRUG@ **obinutuzumab** @DRUG@ @POS@

- 2) **Recognizing drugs that are not part of a combination:** There are occasions where the language contained in the sentence may not be conclusive enough to distinguish between a real combination in comparison with drugs that are being discussed as individual treatments. To drive this home, let’s look at this sentence: “**Dexamethasone** and **piroxicam** provided in the diet were found to significantly inhibit lung tumors induced by 60 mg/kg vinyl carbamate at 24 weeks whereas **myo-inositol** also provided in the diet, did not significantly inhibit tumor formation.” Here the gold annotation indicated that **Dexamethasone** and **piroxicam** are in a POS relation but our model predicted that all three drugs (including **myo-inositol**) are part of a size-3 COMB relation. The model was unable to notice that **myo-inositol** is not part of the combination.
- 3) **Distinguishing between POS and COMB relations:** At times, it was not straightforward from the intra-sentence context to determine whether a combination is effective or non-positive. Getting these relations right may need more complex multi-hop reasoning across different sentences of the abstract. Case in point is this sentence: “Randomized trial of **lenalidomide** alone versus **lenalidomide** plus **rituximab** in patients with recurrent follicular lymphoma : CALGB 50401 (Alliance).” The gold annotation for this is a POS relation consisting of **lenalidomide** and **rituximab**. However, the model predicted a COMB relation, which seems quite plausible when we examine the sentence. In fact, searching for this sentence on PubMed shows that this is the title of an article describing a clinical trial. The title does

not give away enough information about whether the combination was effective or not, but the full abstract which was used by human annotators explicitly says that the combination is effective.

- 4) **Need for external domain knowledge:** Training data may not have enough examples of indirect and implicit ways of communicating efficacy of medications. As such, external domain knowledge about biomedical concepts maybe needed to correctly capture certain relations. To demonstrate this, consider the sentence: “**Growth inhibition** and **apoptosis** were significantly **higher** in BxPC-3, HPAC, and PANC-1 cells treated with **celecoxib** and **erlotinib** than cells treated with either **celecoxib** or **erlotinib**.” Here efficacy is implicitly conveyed through the phrases “growth inhibition” and “apoptosis” and the quantifier “higher”. The former two refer to concepts in disease mechanisms indicating that tumor cell production is lowered or tumor cells are dying, both implying a potential therapeutic effect. Thus, the gold POS relation between **celecoxib** and **erlotinib** is missed by our model, which predicted as a COMB link.

VI. EXPERIMENTS WITH LONGER CONTEXTS

Thus far all our experiments were conducted using the input sentence that contained the drug names without considering any surrounding context from the enclosing full abstract. As was already alluded to in Section IV, 2/3 of the instances in **CombDrugExt** needed human annotators to consider other sentences outside the input sentence containing drug names [2] to determine the correct labels. This behooves us to build models that consider n sentences to the left and right of the main input sentence. We varied n from 1 to 4 to better assess Seq2Rel’s ability to work with a broader context. We added a special [SEP] token surrounding the relation-bearing sentence to inform the model that the task only considers drug entities and combinations expressed in the target sentence while it is still allowed to consider the neighboring context outside it.

We present our evaluation results in Table VII, which clearly shows that considering additional context did not really help our situation. The first row (copy pasted from the last row of our main results Table IV) is clearly better than all other rows. A phenomenon that can be observed is that as n goes from 1 to 4, the recall increases monotonously (and so does

Table VI: Examples of the extended linearization schema for both NER and relation extraction

Relations	Example
Positive Combination	Dexamethasone and piroxicam provided in the diet were found to significantly inhibit lung tumors induced by 60 mg/kg vinyl carbamate at 24 weeks whereas myo-inositol also provided in the diet, did not significantly inhibit tumor formation.
	Dexamethasone; piroxicam; myo-inositol @NER@ Dexamethasone; piroxicam @POS@
Not a Combination	The results showed that lamotrigine did not produce any change in cognitive function, while carbamazepine produced cognitive dysfunction.
	lamotrigine; carbamazepine @NER@

Table VII: The effect of considering a context of n sentences on either side of the relation-bearing sentence.

Model	F_1	P	R
No additional context	66.7	68.1	65.3
1 sentence of context	58.3	63.2	54.0
2 sentences of context	62.8	68.5	58.0
3 sentences of context	65.7	69.9	62.0
4 sentences of context	66.2	67.8	64.7

the F1-score). This gives us the impression that more context seems to help but it is still not able to beat the score when no additional context is used. This is in contrast with the findings of Tiktinsky et al. [2] where extra context appeared to help. However, there is a crucial difference between their and our evaluation process — the entities are provided and locked-in before the relations are predicted for them but our model is end-to-end and has to generate entities from the input. As such, the extra context may have confused our model in fetching the right entities, while it could have helped their span based approach with fixed entity locations.

VII. DRUG NER PLUS CST EXPERIMENT

Please recall that the way the CDT extraction task was designed originally (Section II-B), the model only outputs drug entities that are part of a POS or COMB relations; drugs that are not part of any such relations are not output unless the input is a sentence where neither POS nor COMB relations occur. Thus named entity recognition (NER) of drugs in a comprehensive sense is not integral to the CDT task. This is a reasonable setting because in many cases, one may not be interested in drugs that do not form part of an interesting combination. However, there might be other scenarios where one may want to output all drug mentions even if they are not part of a relation. This could be for computing distributional statistics or to design more complex knowledge discovery applications. Since the annotation of **CombDrugExt** does contain all drug spans (even those that do not participate in a relation), we can design an extended CDT task where both entities and relations are required to be output (regardless of whether entities are part of a relation). This is the task we model in this section.

To also capture all drug entities, for POS and COMB relations, we extend the original linearization schema by pre-pending all the entities mentioned in the sentence before relations are

enumerated. For NOCOMB instances, only the entities are to be output (as the relation is self-explanatory when we do not see POS or COMB labels). Our extended linearization schema is shown in Table VI, where we can see the new special token @NER@ as a delimiter to indicate the end of the entity list before relation enumeration begins. We also replaced the @DRUG@ token with a semicolon here for simplification, especially since we are already listing all drugs upfront. The first POS example shown in the table has three drugs listed for NER using this extended schema; **myo-inositol** would not have been part of the output in the original schema.

From Table VIII, we see that a Seq2Rel model trained with this updated linearization schema (for both NER and CDT) achieves an F1-score of 94% for drug NER. However, there is a dip of around 1% in POS F1-score compared to the approach without the NER output (last row of Table IV). But surprisingly the ANY-COMB F1-score is clearly better (by at least 1.3%) than the corresponding scores obtained through both 2-way and 3-way models as per the original approach (from Table III). Given the ability to achieve high NER score, along with high scores for POS (within 1% of SoTA) and ANY-COMB (new SoTA), we believe this approach of jointly accounting for both entities and relations is better than the original approach that outputs only relations.

Table VIII: End-to-end drug NER and CDT extraction precision, recall, and F_1 -scores for POS and ANY-COMB using the linearization schema from Table VI.

Task	F_1	P	R
NER	94.0	93.5	94.5
POS Combination CDT	65.8	64.9	66.7
Any Combination CDT	74.0	75.9	72.2

VIII. LEFT-TO-RIGHT LINEARIZATION SCHEMA

In Section III-A, linearization simply followed the order in which the drug spans and combinations were ordered by the creators of **CombDrugExt**. While this order was often the left-to-right order in the input sentence, this was not always the case. However, the original Seq2Rel method [3] uses a strict left-to-right ordering of entity spans as observed in the input sentence during training time. Of course, at test time, ordering is irrelevant as we are matching sets (not lists). We also experimented with this left-to-right ordering. That is, in the

linearized output, a combination involving drugs that appear earlier in the sentence appears before another combination whose constituent drugs appear later. If two combinations share a drug, the order of the remaining unshared drugs in the input sentence determines combination order in the output⁵. The results were very similar to results showed thus far in the paper with minor variations: $< 1\%$ performance shifts that are not always in favor of the original or left-to-right order. So we believe these variations are not worth discussing in the rest of this paper.

IX. RELATED WORK

Biomedical relation extraction (RE) has mostly focused on a sub-problem, where the entities are assumed to be already provided, making it a relation classification problem [11]–[14]. In the end-to-end setting, raw textual input is provided and the task is to simultaneously output both entities and relations. While there is merit in considering non end-to-end settings in complex RE problems, overall the end-to-end setup is more realistic for assessment and evaluation for application design. There has been a recent surge in end-to-end approaches in the general RE domain. These can be classified into two main types: (1) A pipeline approach that feeds the output of an NER model to a relation classification model [10]. (2) A joint modeling approach that simultaneously extracts both entities and relations [15]–[17]. In particular, sequence-to-sequence models for end-to-end relation extraction have been on the rise [3], [7], [18], [19] that tend to fall in the joint modeling group of methods. Especially, these approaches easily lend themselves to the dynamic n -ary nature of the CDT extraction task and hence we employ them in this paper.

There are few efforts in biomedical natural language processing that handle drug-disease treatment relations. Kilicoglu et al. [20] present a broad coverage hybrid system to extract different types of relations, which also includes treatment relations. Dumitrache et al. [21] release one of the few publicly available datasets with both expert annotated and crowd sourced treatment relation annotations. n -ary relation extraction datasets are also not widely available in biomedicine with the major exception of drug-gene-mutation relations [22]. Finally, Tiktinsky et al. [2] are the first to annotate and publicly release a dataset for drug combinations, which forms the main focus of our manuscript.

X. CONCLUSION

In this study, we adapted an end-to-end relation extraction approach based on sequence-to-sequence methods for extracting drug combinations that are part of combination drug therapies. The resulting Seq2Rel models use linearization schemes to encode entities and relations as output sequences for training the models and to use them in the generation mode for testing. We showed that this approach results in

⁵More formally, the drug spans form a finite total order based on their left to right positioning in the input sentence. Our linearization strategy is based on the well-known extension of a total order on a finite set (drug spans) to a total order on its power set (drug combinations).

new state-of-the-art performances on the **CombDrugExt** dataset in the end-to-end setting that improve even over non end-to-end baselines (by nearly 5% in F1-score), established by prior efforts. We see five important directions for future efforts:

- As highlighted in Section II-A, the **CombDrugExt** dataset does not include the target disease, which we believe is central to any future work on this problem. We propose to extend **CombDrugExt** by specifically adding this extra piece of information to make it a more complete dataset for CDT extraction.
- As per our results in Section VI, our method, as it stands, is unable to take advantage of the additional full abstract context available. We plan to further adapt Seq2Rel methods to take advantage of potential multi-hop links that are present in the broader context of the enclosing abstract. Based on manual examination of some errors, we believe co-references of the participating drug combinations may need to be handled more carefully.
- A minor issue with order selection in linearization (Sections III-A and VIII) is that during training time, we unfairly penalize the target tokens if they do not exactly match the order we specify, even if they are in essence representing the same combination. We believe that an ensemble model where each constituent model trains with a different valid output order that nevertheless encodes the same combinations may perform much better than any single model trained with a fixed order. This is a hypothesis we aim to test in the future.
- It may be important to qualify our end-to-end formulation in Section II-B with a caveat. Although we do not assume that the drug spans are available upfront, we still assume that the sentence that contains the names of all participating drugs is available. Ideally, for CDT extraction to be truly end-to-end, our method ought to extract relations given the full abstract without any index of the sentence containing the potential combination. A future direction would be to operate without the knowledge of the sentence containing the drug names. However, this might need additional human curated annotations and may be a more expensive process.
- In Section V we identified different types of errors, one of which was due to the dependence on domain knowledge about treatment mechanisms through which drugs operate; we surmised that this knowledge may not have been available from the language variation in the training examples. A future direction would be to imbue this domain knowledge into the modeling process for CDT extraction, potentially through external knowledge graphs of biomedical processes. Of course, in this case, for fair comparison, this external knowledge should also be provided in some manner along with the dataset for benchmarking by the wider community.

REFERENCES

- [1] F. Klauschen, M. Andreeff, U. Keilholz, M. Dietel, and A. Stenzinger, "The combinatorial complexity of cancer precision medicine," *Oncoscience*, vol. 1, no. 7, p. 504, 2014.
- [2] A. Tiktinsky, V. Viswanathan, D. Niezni, D. Meron Azagury, Y. Shamay, H. Taub-Tabib, T. Hope, and Y. Goldberg, "A dataset for n-ary relation extraction of drug combinations," in *Proceedings of the 2022 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*. Seattle, United States: Association for Computational Linguistics, Jul. 2022, pp. 3190–3203. [Online]. Available: <https://aclanthology.org/2022.naacl-main.233>
- [3] J. Giorgi, G. Bader, and B. Wang, "A sequence-to-sequence approach for document-level relation extraction," in *Proceedings of the 21st Workshop on Biomedical Language Processing*. Dublin, Ireland: Association for Computational Linguistics, May 2022, pp. 10–25. [Online]. Available: <https://aclanthology.org/2022.bionlp-1.2>
- [4] J. Devlin, M.-W. Chang, K. Lee, and K. Toutanova, "BERT: Pre-training of deep bidirectional transformers for language understanding," in *Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers)*. Minneapolis, Minnesota: Association for Computational Linguistics, Jun. 2019, pp. 4171–4186. [Online]. Available: <https://aclanthology.org/N19-1423>
- [5] S. Hochreiter and J. Schmidhuber, "Long short-term memory," *Neural Computation*, vol. 9, no. 8, pp. 1735–1780, 1997.
- [6] D. Jurafsky and J. H. Martin, *Speech and Language Processing (3rd Edition)*, 2023, <https://web.stanford.edu/~jurafsky/slp3/>.
- [7] X. Zeng, D. Zeng, S. He, K. Liu, and J. Zhao, "Extracting relational facts by an end-to-end neural model with copy mechanism," in *Proceedings of the 56th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)*. Melbourne, Australia: Association for Computational Linguistics, Jul. 2018, pp. 506–514. [Online]. Available: <https://aclanthology.org/P18-1047>
- [8] Y. Gu, R. Tinn, H. Cheng, M. Lucas, N. Usuyama, X. Liu, T. Naumann, J. Gao, and H. Poon, "Domain-specific language model pretraining for biomedical natural language processing," *ACM Transactions on Computing for Healthcare (HEALTH)*, vol. 3, no. 1, pp. 1–23, 2021.
- [9] S. Gururangan, A. Marasović, S. Swayamdipta, K. Lo, I. Beltagy, D. Downey, and N. A. Smith, "Don't stop pretraining: Adapt language models to domains and tasks," in *Proceedings of the 58th Annual Meeting of the Association for Computational Linguistics*. Online: Association for Computational Linguistics, Jul. 2020, pp. 8342–8360. [Online]. Available: <https://aclanthology.org/2020.acl-main.740>
- [10] Z. Zhong and D. Chen, "A frustratingly easy approach for entity and relation extraction," in *Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*. Online: Association for Computational Linguistics, Jun. 2021, pp. 50–61. [Online]. Available: <https://aclanthology.org/2021.naacl-main.5>
- [11] B. Rink, S. Harabagiu, and K. Roberts, "Automatic extraction of relations between medical concepts in clinical texts," *Journal of the American Medical Informatics Association*, vol. 18, no. 5, pp. 594–600, 2011.
- [12] R. Kavuluru, A. Rios, and T. Tran, "Extracting drug-drug interactions with word and character-level recurrent neural networks," in *2017 IEEE International Conference on Healthcare Informatics (ICHI)*. IEEE, 2017, pp. 5–12.
- [13] S. Liu, K. Chen, Q. Chen, and B. Tang, "Dependency-based convolutional neural network for drug-drug interaction extraction," in *2016 IEEE international conference on bioinformatics and biomedicine (BIBM)*. IEEE, 2016, pp. 1074–1080.
- [14] Y. Peng, A. Rios, R. Kavuluru, and Z. Lu, "Extracting chemical–protein relations with ensembles of svm and deep learning models," *Database*, vol. 2018, 2018.
- [15] M. Miwa and M. Bansal, "End-to-end relation extraction using lstms on sequences and tree structures," in *Proceedings of the 54th Annual Meeting of the Association for Computational Linguistics (Volume 1: Long Papers)*, 2016, pp. 1105–1116.
- [16] T. Tran and R. Kavuluru, "Neural metric learning for fast end-to-end relation extraction," *arXiv preprint arXiv:1905.07458*, 2019.
- [17] G. Bekoulis, J. Deleu, T. Demeester, and C. Develder, "Joint entity recognition and relation extraction as a multi-head selection problem," *Expert Systems with Applications*, vol. 114, pp. 34–45, 2018.
- [18] D. Zeng, H. Zhang, and Q. Liu, "Copymtl: Copy mechanism for joint extraction of entities and relations with multi-task learning," in *Proceedings of the AAAI conference on artificial intelligence*, vol. 34, no. 05, 2020, pp. 9507–9514.
- [19] T. Nayak and H. T. Ng, "Effective modeling of encoder-decoder architecture for joint entity and relation extraction," in *Proceedings of the AAAI conference on artificial intelligence*, vol. 34, no. 05, 2020, pp. 8528–8535.
- [20] H. Kilicoglu, G. Roseblat, M. Fiszman, and D. Shin, "Broad-coverage biomedical relation extraction with semrep," *BMC bioinformatics*, vol. 21, pp. 1–28, 2020.
- [21] A. Dumitrache, L. Aroyo, and C. Welty, "Crowdsourcing ground truth for medical relation extraction," *ACM Transactions on Interactive Intelligent Systems (TiiS)*, vol. 8, no. 2, pp. 1–20, 2018.
- [22] N. Peng, H. Poon, C. Quirk, K. Toutanova, and W.-t. Yih, "Cross-sentence n-ary relation extraction with graph LSTMs," *Transactions of the Association for Computational Linguistics*, vol. 5, pp. 101–115, 2017. [Online]. Available: <https://aclanthology.org/Q17-1008>